MTOR and Miyoshi myopathy: In conclusion, the effectivity of a brain penetrant dual PI3K/mTOR inhibitor in low doses particularly on the prevention of brain metastases makes this approach to a plausible road for a future BM prevention trial in high-risk MM patients.